# Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

> **NCT01861496** · PHASE1,PHASE2 · COMPLETED · sponsor: **Allarity Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Phase 1: Advanced or Refractory Solid Tumours
- Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

## Interventions

- **DRUG:** LiPlaCis

## Key facts

- **NCT ID:** NCT01861496
- **Lead sponsor:** Allarity Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01861496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01861496, "Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01861496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*